Healthcare private equity firms are in the crosshairs of the US antitrust agencies, the White House, state legislators, and some prominent members of Congress.
In recent weeks, Federal Trade Commission (FTC) Chair Lina Khan has argued that private equity acquisitions of healthcare practices have “enabled firms to amass significant control over key services in local markets,” resulting in “fewer choices and higher costs” for patients and payors. States such as California, New York and several others are enacting new laws and restrictions on private equity ownership of healthcare companies.
Meanwhile, the Chair of the Senate Finance Committee has argued that healthcare consolidation, particularly by private equity, allegedly results in “increasing costs without improving the quality of care.”
The risk factors are intensifying as… Read more
